# Symbiotic-Lung-01 (NCT07222566)

> Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: PF-08634404
- Indication: locally advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07222566
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Advanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; Carcinoma, Non-Small-Cell Lung (NSCLC); Metastatic Non Small Cell Lung Cancer; Lung Cancer
- Interventions: PF-08634404; Pembrolizumab; Chemotherapy Regimen 1; Chemotherapy Regimen 2
- Enrollment: 1410
- Primary outcome: Overall Survival
- Primary outcome: Progression Free Survival (PFS) assessed by blinded independent central review (BICR)

## Indexed commentary on Symbiotic-Lung-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=symbiotic-lung-01-nct07222566